TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15105183

Group type: EXPERIMENTAL
Intervention: Controlled intervention aimed at increasing fruit and vegetable consumption for 1 month
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Controlled intervention aimed at increasing fruit and vegetable consumption for 1 year
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Baseline consumption of fruits
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Baseline consumption of vegetables
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Changes in fruit consumption
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Changes in vegetable consumption
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study: 11999592

Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block with 25 mL mepivacaine 2% (15 mL for femoral nerve, 10 mL for sciatic nerve)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthetic with continuous intravenous infusion of remifentanil (0.1-0.3 microgkg(‐1) min(‐1)) and propofol (target plasma concentration 2-4 microg mL(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 40
Study: 9657355

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II (i.v. infusion for 60 min at doses of 4, 8, and 16 ng/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7616840

Group type: EXPERIMENTAL
Intervention: Exercise (15-minute test including 5 minutes of increasing workload followed by 10 minutes at 85% of maximal heart rate)
Number of subjects: 7
Study: 2589861

Group type: EXPERIMENTAL
Intervention: RS-85095
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RS-21314
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol 17-propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocinonide
Number of subjects: 0
Study: 330302

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g, three times daily for 3 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Routine treatment (dietary restriction and ad libitum antacid)
Number of subjects: 16
Study: 6119939

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg of morphine (postoperative)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 50 mg of pethidine (postoperative)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 0.1 mg of fentanyl (postoperative)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg of morphine (peroperative)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: fentanyl (peroperative)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: epidural injection of morphine after neuroleptoanaesthesia
Number of subjects: 404
Study: 31135084

Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a for 48 weeks
Number of subjects: 133

Group type: COMPARATOR
Intervention: HBV DNA and qHBsAg decline at week 12
Number of subjects: 133
Study: 28823835

Group type: EXPERIMENTAL
Intervention: Guanfacine (up to 3mgs)
Number of subjects: 40
Study: 26371360

Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education and Support (DSMES)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study: 23404948

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGBP) combined with omentectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Roux‐en‐Y gastric bypass (RYGBP) alone
Number of subjects: 20
Study: 21558167

Group type: EXPERIMENTAL
Intervention: Inductive reasoning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global mental status
Number of subjects: 0
Study: 18953607

Group type: EXPERIMENTAL
Intervention: Trained clinician ratings by speech-language pathologists (SLPs)
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Use of the 8-point Penetration/Aspiration Scale by SLPs
Number of subjects: 669
Study: 17968815

Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg administered 10 hours and 1.5 hours prior to nifedipine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine (10 mg) alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine and silymarin co-administration
Number of subjects: 16
Study: 15156430

Group type: EXPERIMENTAL
Intervention: Once-daily HAART
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Twice-daily HAART
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 54
Study: 12168960

Group type: EXPERIMENTAL
Intervention: 13‐cis retinoic acid (13‐CRA)
Number of subjects: 28
Study: 10553804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SS-cream 0.05 g
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SS-cream 0.10 g
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SS-cream 0.15 g
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SS-cream 0.20 g
Number of subjects: 50
Study: 7598236

Group type: EXPERIMENTAL
Intervention: IVRA with 0.5% lidocaine and IV ketorolac (K)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVRA with 0.5% lidocaine (control group)
Number of subjects: 60
Study: 2119153

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg IV bolus)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alfentanil (50 micrograms/kg IV bolus followed by infusion at 1 micrograms.kg‐1.min‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: N2O-O2 (control group)
Number of subjects: 24
Study: 710268

Group type: EXPERIMENTAL
Intervention: Social skills training (SST)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional supportive therapy (TST)
Number of subjects: 24
Study: 31079028

Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (mood stabilizers included)
Number of subjects: 37
Study: 28470371

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 64
Study: 25336357

Group type: EXPERIMENTAL
Intervention: Phased radio frequency (pRF) ablation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Irrigated radio frequency (iRF) ablation
Number of subjects: 76
Study: 24089054

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (1 g/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22155673

Group type: EXPERIMENTAL
Intervention: Web-based intervention comprising 4 sessions of tailored motivational messages and self-regulation support (n = 324)
Number of subjects: 517

Group type: COMPARATOR
Intervention: No-intervention control group (n = 179)
Number of subjects: 517
Study: 19786674

Group type: EXPERIMENTAL
Intervention: Decision aid for diabetes medication choice
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study: 16679275

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (CNR > 35.86)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Proton MRS (choline/creatine ratio > 1.56)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined model (CNR, choline/creatine ratio, presence of lactates)
Number of subjects: 35
Study: 15246627

Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (2.5 microg - 10 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (lower three dose levels)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (high doses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prolonged booster immunizations
Number of subjects: 50
Study: 12218721

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (70 mg genistin and daidzin per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract
Number of subjects: 75
Study: 9584874

Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7619676

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan (5-HTP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP)
Number of subjects: 6
Study: 11527139

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 3234
Study: 362297

Group type: EXPERIMENTAL
Intervention: testololactone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: drostanolone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: nandrolone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: cyclophosphamide (additional treatment during second interval)
Number of subjects: 91
Study: 30368163

Group type: EXPERIMENTAL
Intervention: MSI-195 800 mg added to ongoing ADT
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo added to ongoing ADT
Number of subjects: 234
Study: 26730569

Group type: COMPARATOR
Intervention: Continuous ART
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Planned Treatment Interruption (PTI)
Number of subjects: 88
Study: 25298577

Group type: EXPERIMENTAL
Intervention: Risperidone (RSP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Olanzapine (OZP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between RSP and OZP
Number of subjects: 64
Study: 22001689

Group type: EXPERIMENTAL
Intervention: Written materials and basic Web access (RCT1)
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Interactive Web site (RCT2)
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Brief telephone/e‐mail coaching support (RCT3)
Number of subjects: 1755
Study: 21516922

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% (LIDO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal saline with preservatives (NSP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline without preservatives (NS)
Number of subjects: 60
Study: 17268258

Group type: EXPERIMENTAL
Intervention: Workplace intervention
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study: 16136947

Group type: EXPERIMENTAL
Intervention: Composite Xin Mai Tong (XMT) capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12189365

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg to 40 mg once daily)
Number of subjects: 21
Study: 10338353

Group type: EXPERIMENTAL
Intervention: Lofric catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: EasiCath catheter
Number of subjects: 20
Study: 8750400

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice daily for 3 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 1780419

Group type: EXPERIMENTAL
Intervention: Light inhaling smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep inhaling smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smoking subjects (controls)
Number of subjects: 0
Study: 6110654

Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to neuroleptic treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30657056

Group type: EXPERIMENTAL
Intervention: Educational intervention (specific training in safety, incident recording over 15 days, feedback on performance)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no action taken)
Number of subjects: 138
Study: 28978543

Group type: EXPERIMENTAL
Intervention: Cream cheese
Number of subjects: 43

Group type: COMPARATOR
Intervention: Butter (control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cheddar cheese
Number of subjects: 43
Study: 27852706

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (BoNT‐A) injection guided by electrostimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (BoNT‐A) injection guided by ultrasound
Number of subjects: 30
Study: 24468886

Group type: EXPERIMENTAL
Intervention: GCPGC at 100 μg/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GCPGC at 30-100 μg/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GCPGC at 300 μg/kg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pegfilgrastim at 100 μg/kg
Number of subjects: 25
Study: 22081256

Group type: EXPERIMENTAL
Intervention: Clopidogrel tapering (75 mg every other day for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Abrupt cessation of clopidogrel (Off group)
Number of subjects: 20
Study: 20853929

Group type: EXPERIMENTAL
Intervention: Telephone intervention delivered by counselors
Number of subjects: 2151
Study: 18065578

Group type: EXPERIMENTAL
Intervention: Oily fish (salmon and albacore tuna) - 2 servings per week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fish-oil capsules - 1-2 capsules per day
Number of subjects: 22
Study: 16617852

Group type: EXPERIMENTAL
Intervention: Group 1 (MMU-simulator with additional strain in the second interval)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Group 2 (MMU-simulator with additional strain in the first interval)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Group 1 (blood sampling for hormone analysis)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Group 1 and Group 2 (comparison of strain vs rest)
Number of subjects: 23
Study: 12412493

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training or prior experience
Number of subjects: 0
Study: 10217331

Group type: EXPERIMENTAL
Intervention: Atropine (10 microg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (5 microg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine (5 microg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8688981

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg t.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1318083

Group type: EXPERIMENTAL
Intervention: Clonidine (100 micrograms IV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (15 healthy men)
Number of subjects: 19
Study: 6496286

Group type: EXPERIMENTAL
Intervention: Verapamil (453 ± 75 mg per day) + Isosorbide dinitrate (117 ± 63 mg per day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine (71 ± 14 mg per day) + Isosorbide dinitrate (117 ± 63 mg per day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (117 ± 63 mg per day) alone
Number of subjects: 9
Study: 31004135

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) with ferrous fumarate (FeFum) in water
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) with ferrous fumarate (FeFum) in a test meal
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) with ferrous fumarate (FeFum) in a test meal after 4 weeks of GOS consumption
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FeSO4) in a test meal with GOS after 4 weeks of GOS consumption
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ferrous fumarate (FeFum) in a test meal without GOS after 4 weeks of GOS consumption
Number of subjects: 34
Study: 29902299

Group type: EXPERIMENTAL
Intervention: Dual HER2-targeted therapy (lapatinib and trastuzumab)
Number of subjects: 245
Study: 27357281

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) neopterin levels in delirium patients (median 29.6 nmol/mL)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Serum neopterin levels in delirium patients (median 37.0 nmol/mL)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CSF neopterin levels
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Higher neopterin levels (CSF and serum)
Number of subjects: 139
Study: 26179185

Group type: EXPERIMENTAL
Intervention: Dietary NO3 (‐) from beetroot juice (11.2 mmol)
Number of subjects: 9
Study: 22999380

Group type: EXPERIMENTAL
Intervention: CRA plus vouchers program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Community reinforcement approach (CRA) treatment
Number of subjects: 118
Study: 20459475

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) - 572.8 mg tea catechins (TC) daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA) - 0 mg tea catechins (TC) daily
Number of subjects: 12
Study: 18946457

Group type: EXPERIMENTAL
Intervention: Supplementation of five micronutrients (vitamin A, vitamin C, vitamin E, folic acid, and zinc)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Single micronutrient supplementation (in sub-groups)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no micronutrient supplementation)
Number of subjects: 800
Study: 16820802

Group type: COMPARATOR
Intervention: Standard sodium fluoride dentifrice (treatment period 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard sodium fluoride dentifrice (treatment period 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Antimicrobial stannous fluoride/sodium hexametaphosphate dentifrice (treatment period 3)
Number of subjects: 16
Study: 14617230

Group type: EXPERIMENTAL
Intervention: BIAsp 70 (Dinner70 regimen)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIAsp 50 (Dinner50 regimen)
Number of subjects: 16
Study: 10763941

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg q.a.m.
Number of subjects: 376

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 376
Study: 9149895

Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ) screening for dietary eligibility
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Revised criteria for FFQ screening
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Target calcium and dietary fiber values
Number of subjects: 183
Study: 8429120

Group type: EXPERIMENTAL
Intervention: RRR alpha-tocopherol
Number of subjects: 12
Study: 3119287

Group type: EXPERIMENTAL
Intervention: Two silastic rods (Norplant)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Six capsules (Norplant)
Number of subjects: 250
Study: 30305280

Group type: EXPERIMENTAL
Intervention: Eltrombopag (200 mg/d, max 300 mg/d for East Asians) plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus azacitidine
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo plus azacitidine
Number of subjects: 356
Study: 26528941

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.02 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 25180479

Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet rich in ALA (3.4 g/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Hypoenergetic diet low in ALA (0.9 g/d, control)
Number of subjects: 81
Study: 22857017

Group type: EXPERIMENTAL
Intervention: Automated, interactive telephone-delivered management intervention (TLC Diabetes)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual routine care
Number of subjects: 120
Study: 21169251

Group type: EXPERIMENTAL
Intervention: Erlotinib added to gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 17611913

Group type: COMPARATOR
Intervention: Conventional chromoendoscopy with acetic acid (CAA)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy (CVC)
Number of subjects: 57
Study: 16037757

Group type: EXPERIMENTAL
Intervention: Topical vaginal estrogen therapy (ET group)
Number of subjects: 56
Study: 12400824

Group type: EXPERIMENTAL
Intervention: Electron beam coronary angiography
Number of subjects: 27
Study: 8049820

Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU/d), Calcium (1 g/d), EHDP (7.5 mg/kg body weight)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 33
Study: 2838923

Group type: EXPERIMENTAL
Intervention: Kabi 2165 (2,500 anti-Xa units once daily)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU twice daily)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Kabi 2165
Number of subjects: 385
Study: 31786983

Group type: EXPERIMENTAL
Intervention: Esaxerenone 2.5 mg/day
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Esaxerenone 5 mg/day
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Eplerenone 50 mg/day
Number of subjects: 1001
Study: 30969910

Group type: EXPERIMENTAL
Intervention: Auditec version of NU-6
Number of subjects: 48

Group type: COMPARATOR
Intervention: VA version of NU-6
Number of subjects: 48
Study: 28472415

Group type: EXPERIMENTAL
Intervention: Acupressure treatment (15 min, 4 times a week for 12 weeks)
Number of subjects: 100
Study: 25576474

Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lower-Limb Exercises
Number of subjects: 94
Study: 23497934

Group type: EXPERIMENTAL
Intervention: Preoperative non-invasive ventilation for 7 days at home
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study: 21525252

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet plus aerobic exercise (5 d · wk(‐1), 60 min · d(‐1), 80‐85% heart rate(max))
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-glycemic index diet plus aerobic exercise (5 d · wk(‐1), 60 min · d(‐1), 80‐85% heart rate(max))
Number of subjects: 28
Study: 19048237

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 7
Study: 16954548

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 20